NEW YORK — A large number of eyes with newly diagnosed wet age-related macular degeneration received insufficient treatment, leading to poor outcomes and vision loss, according to a study.
In a presentation at the American Society of Retina Specialists annual meeting, Anita Barikian, MD, said despite the demonstrated benefit of anti-VEGF therapy in wet AMD, challenges in managing the disease can affect patient outcomes.
To better understand the relationship between treatment patterns and outcomes, Barikian and colleagues explored data from the IRIS Registry, including treatment-naive eyes